chromosome 17 open reading frame 50Genealiases: []
Q-omics provides the consensus-scored C17orf50 profile across patient tissues and cancer cell-line models. C17orf50 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C17orf50 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, C17orf50 RNA expression shows 12,334 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRC, and LAML as cancer lineages where C17orf50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C17orf50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C17orf50 survival associations across molecular data types. C17orf50 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C17orf50 RNA expression–survival associations across cancer types. High C17orf50 expression shows unfavorable associations in KIRC, LUSC and UVM, but favorable associations in HNSC, CESC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C17orf50 RNA expression.
This table summarizes C17orf50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C17orf50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C17orf50 shows lower tumor expression in KIRC, KICH, LUSC, READ and COAD and higher tumor expression in KIRP. The KIRC box plot shows higher C17orf50 RNA expression in normal versus tumor tissue (log2 FC = −0.223, t-test p < 0.001).
This table shows molecular features associated with C17orf50 in patient tissues and cancer cell lines. In patient samples, C17orf50 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, C17orf50 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
